Most people treat biology as a bespoke, messy science. Josh Meier and Matt McPartlon, co-founders of Chai Discovery, treat it as an engineering problem. They make the case that drug design obeys the bitter lesson: scale data, models, and compute, and the model can learn what a hand-built pipeline simply couldn't capture. The results are concrete: Chai-2 pushed de novo antibody design from a sub 0.1% hit rate to 16%, turning a needle-in-a-haystack search into something more like designing a key to fit a lock. Josh argues, counterintuitively, that biology is more verifiable than code, and explains why the goal should be more lab experiments, not fewer. Their bet: a design suite that collapses drug discovery from nine months to nine days, and arms the pharma industry rather than competing with it.
Hosted by Pat Grady and Sonali Singh, Sequoia Capital
01:52 From Discovery to Design
03:25 Protein AI Breakthroughs Timeline
06:04 Why Start in 2024
10:13 Diffusion Models Intuition
11:41 Building the Avengers Team
15:22 Hit Rates and Scaling Laws
25:01 Molecular CAD Vision
25:24 Faster Design Loops
26:32 Future Drug Discovery
28:37 Platform Business Model
31:14 Partnering Reality Check
33:44 Data Flywheel Explained
37:16 Staying Ahead at Scale
39:44 Culture and What's Next